RDY250117P5000
- 0.00
- 0.000.00%
Dr. Reddy's Laboratories Newsroom
Asian Equities Traded in the US as American Depositary Receipts Nudge Higher Friday Trading, Up 2.6% for Week
Dr. Reddy's Laboratories Files Q4 2024 Financials With SEC
Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,170 From INR1,210, Keeps at Underperform
Dr. Reddy's Laboratories Posts Gains in Fiscal Q3 Consolidated Profit; Shares Down 4%
Earnings Call Summary | Dr. Reddy's Laboratories(RDY.US) Q3 2025 Earnings Conference
Dr. Reddy's Laboratories Releases Quarterly Financial Report Amidst Industry Challenges
Dr. Reddy's Laboratories | 6-K: Report of foreign private issuer (related to financial reporting)
Earnings Flash (RDY) Dr. Reddy's Laboratories Posts Fiscal Q3 EPS $0.20, Vs. FactSet Est of $0.21
Dr. Reddy's 3Q Rev INR83.59B
Dr. Reddy's Q3 & 9MFY25 Financial Results
Press Release: Dr. Reddy's Q3 & 9MFY25 Financial Results
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading
Express News | Dr. Reddy's Laboratories Shares Are Trading Lower. The Company Reported Q3 Financial Results
Express News | Dr Reddy's Laboratories Q3 2025 GAAP EPS $0.20 Versus $0.19 YoY, Sales $977.00M Compared To $843M YoY
Earnings Scheduled For January 23, 2025
Trump's Cannabis Reform: Mike Tyson, Weldon Angelos Say President Can Get It Done
Here's the Major Earnings Before the Open Tomorrow
Dr. Reddy's Laboratories Faces Legal Challenges Over Revlimid Patent Settlement
Dr. Reddy's Q3 2025 Earnings Preview
BofA Securities Maintains Dr. Reddy's Laboratories(RDY.US) With Buy Rating, Raises Target Price to $19.4